Ultragenyx (RARE) Jumped 7.5% on FDA Approval. Can a $2.7 Million Gene Therapy Become a Commercial Success?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw a 7.5% jump in after-hours trading on Wednesday after the FDA approved Genglycos, a gene therapy for glycogen storage disease type Ia (GSDIa). This marks Ultragenyx's first FDA approval for a treatment tackling the disease's underlying cause. The therapy, priced at approximately $2.7 million per patient, is set to launch through qualified treatment centers within 30 to 60 days.

This approval grants Ultragenyx first-mover advantage in a market of only 1,500 to 2,500 Americans affected by the disorder. GSDIa impairs the liver's ability to release glucose, leaving patients reliant on frequent cornstarch doses to prevent life-threatening hypoglycemia. Phase 3 GlucoGene trial data showed Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared to a 10% reduction for placebo.

Such reductions in patient burden support a premium price for Genglycos. Ultragenyx manufactures Genglycos in its Bedford, Massachusetts facility, which could provide a blueprint for future gene therapies. The company's existing pipeline includes rare-disease products such as Crysvita, Dojolvi, Evkeeza, and Mepsevii, giving it a functional commercial base.

Genglycos' $2.7 million list price could generate substantial gross revenue per patient, though discounts, rebates, and access arrangements will likely affect the actual price paid by insurers. Still, Ultragenyx must locate eligible patients, secure payer approval, and move them through treatment centers. The therapeutic market remains small, and annual demand may wane after the initial cohort of patients receives treatment.

Despite this, Ultragenyx maintains a strong position with a premium price, robust manufacturing capabilities, and evidence of Genglycos' effectiveness in reducing an arduous daily treatment regimen. The approval supports the company's gene-therapy platform, but financial success hinges on patient diagnosis, reimbursement, and treatment adherence.

Ultragenyx already holds positions in 55 hedge funds, with a majority remaining unchanged since the previous quarter. While RARE shows promise, Insider Monkey suggests other AI stocks may offer higher upside potential and lower risk.